ARDELYX, INC. (ARDX) Shares outstanding analysis
- Shares outstanding · latest quarter: Value 249.19M; Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 1 year ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 5 years ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares change · vs previous quarter: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
Shares outstanding analysis
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Shares outstanding · latest quarter | 249.19M | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 1 year ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 5 years ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
| Shares count change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current quarter shares | 249.19M shares | |
| Previous quarter shares | (m) |
Shares means common shares outstanding, adjusted to the same split basis for comparison. It is a count, not USD or convertible securities; B means billion shares.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current quarter shares (shares) | Shares count change · vs previous quarter | Shares change (%) · vs previous quarter |
|---|---|---|---|
| 2026-06-30 | 249.19M | (m) | (m) |
| 2026-03-31 | 247.03M | (m) | (m) |
| 2025-12-31 | 245.25M | (m) | (m) |
| 2025-06-30 | 240.98M | (m) | (m) |
| 2025-03-31 | 239.26M | (m) | (m) |
| 2024-12-31 | 238.36M | (m) | (m) |
| 2024-09-30 | 236.85M | (m) | (m) |
| 2024-06-30 | 235.43M | (m) | (m) |
| 2024-03-31 | 233.98M | (m) | (m) |
| 2023-09-30 | 232.14M | (m) | (m) |
| 2023-06-30 | 217.86M | (m) | (m) |
| 2023-03-31 | 214.46M | (m) | (m) |
| 2022-12-31 | 206.49M | (m) | (m) |
| 2022-09-30 | 187.46M | (m) | (m) |
| 2022-06-30 | 154.64M | (m) | (m) |
| 2022-03-31 | 144.60M | (m) | (m) |
| 2021-12-31 | 130.29M | (m) | (m) |
| 2021-09-30 | 112.74M | (m) | (m) |
| 2021-06-30 | 103.12M | (m) | (m) |
| 2021-03-31 | 98.71M | (m) | (m) |
| 2020-12-31 | 98.68M | (m) | (m) |
| 2020-09-30 | 90.25M | (m) | (m) |
| 2020-06-30 | 89.14M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |